-
公开(公告)号：US20060239975A1
公开(公告)日：2006-10-26
申请号：US11475827
申请日：2006-06-27
申请人： Gary Nabel , Zhi-yong Yang , Elizabeth Nabel
发明人： Gary Nabel , Zhi-yong Yang , Elizabeth Nabel
CPC分类号： C12N15/86 , A61K9/0019 , A61K31/70 , A61K31/711 , A61K38/1709 , A61K38/1774 , A61K38/45 , A61K48/005 , C12N2710/10343 , A61K2300/00
摘要： The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0/G1, alteration in morphology, and cell differentiation.
摘要翻译： p21基因编码影响细胞周期进程的细胞周期蛋白依赖性激酶抑制剂，但该基因产物在改变肿瘤生长中的作用尚未确定。 本发明人现已发现，通过p21的表达抑制体内恶性细胞的生长。 p21的表达导致细胞在G0 / G1 / 1中的积累，形态的改变和细胞分化。
-
2.发明申请Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo 审中-公开用DNA包被支架的方法和从DNA涂层支架体内重组基因的表达公开(公告)号：US20050038499A1
公开(公告)日：2005-02-17
申请号：US10946785
申请日：2004-09-22
申请人： Elizabeth Nabel , Gary Nabel , Zhi-yong Yang
发明人： Elizabeth Nabel , Gary Nabel , Zhi-yong Yang
CPC分类号： A61L31/16 , A61F2/82 , A61K9/0024 , A61K31/711 , A61K38/45 , A61K38/50 , A61K48/00 , A61L31/10 , A61L2300/252 , A61L2300/258 , A61L2300/416 , A61L2300/606 , C08L89/00
摘要： The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.
摘要翻译： 本发明描述了DNA涂覆的支架及其使用方法来治疗或预防血管疾病如再狭窄。
-
公开(公告)号：US20080095835A1
公开(公告)日：2008-04-24
申请号：US11981179
申请日：2007-10-31
申请人： Gary Nabel , Zhi-yong Yang , Elizabeth Nabel
发明人： Gary Nabel , Zhi-yong Yang , Elizabeth Nabel
IPC分类号： A61K31/711 , A61K9/127 , A61P35/00 , A61P9/00
CPC分类号： C12N15/86 , A61K9/0019 , A61K31/70 , A61K31/711 , A61K38/1709 , A61K38/1774 , A61K38/45 , A61K48/005 , C12N2710/10343 , A61K2300/00
摘要： The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0/G1, alteration in morphology, and cell differentiation.
摘要翻译： p21基因编码影响细胞周期进程的细胞周期蛋白依赖性激酶抑制剂，但该基因产物在改变肿瘤生长中的作用尚未确定。 本发明人现已发现，通过p21的表达抑制体内恶性细胞的生长。 p21的表达导致细胞在G0 / G1 / 1中的积累，形态的改变和细胞分化。
-
4.发明授权Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures 有权编码改良埃博拉病毒糖蛋白的核酸，同时保留天然抗原结构，减少细胞毒性公开(公告)号：US09012618B2
公开(公告)日：2015-04-21
申请号：US13349917
申请日：2012-01-13
申请人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
发明人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5156 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/17022 , C12N2760/14022 , C12N2760/14134 , C12N2840/44
摘要： The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
摘要翻译： 本发明涉及包含编码经修饰的病毒糖蛋白（GP）的多核苷酸的核酸分子，其具有位于所述GP的相对保守区域中的至少一个氨基酸改变，其降低体外细胞毒性并且与体外细胞毒性相比保留免疫原性 野生型病毒GP和相关修饰的病毒GP，质粒DNA，重组病毒，腺病毒，药物组合物，疫苗组合物，与修饰的病毒GP特异性反应的抗体的免疫原性及其制备和使用的相关方法。
-
5.发明申请Targeting gene transfer vectors to certain cell types by pseudotyping with viral glycoprotein 审中-公开通过用病毒糖蛋白假型分型将基因转移载体靶向某些细胞类型公开(公告)号：US20050130129A1
公开(公告)日：2005-06-16
申请号：US10860878
申请日：2004-06-03
申请人： Gary Nabel , Rafael Delgado , Zhi-yong Yang
发明人： Gary Nabel , Rafael Delgado , Zhi-yong Yang
IPC分类号： A61K48/00 , C07K14/08 , C12N15/867 , C12N15/88 , C12Q1/70 , C07K14/005 , C12N7/00 , C12Q1/68
CPC分类号： C12N15/86 , A61K48/00 , C07K14/005 , C12N15/88 , C12N2740/13022 , C12N2740/13043 , C12N2740/13045 , C12N2760/14122 , C12N2810/60 , C12N2840/203
摘要： The present invention provides compositions and methods for targeting gene transfer vectors to certain cell types by pseudotyping with a transmembrane form of viral glycoprotein, such as that from Ebola virus. The methods comprise the step of administering to a cell population a gene to be transferred operatively linked to an appropriate transfer vehicle, wherein the transfer vehicle is associated with a transmembrane form of viral glycoprotein.
摘要翻译： 本发明提供了通过用跨膜形式的病毒糖蛋白（例如来自埃博拉病毒的病毒糖蛋白）的假型分型来将基因转移载体靶向某些细胞类型的组合物和方法。 所述方法包括向细胞群体施用可转移的基因可操作地连接到合适的转运载体的步骤，其中所述转运载体与跨膜形式的病毒糖蛋白缔合。
-
公开(公告)号：US20060275897A1
公开(公告)日：2006-12-07
申请号：US11376484
申请日：2006-03-15
申请人： Gary Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
发明人： Gary Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234
摘要： In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要翻译： 在一个实施方案中，本发明提供了多重HIV质粒DNA或病毒载体疫苗，其包括来自独立进化枝的Env（任选的Env嵌合体）和Gag-Pol-（任选地）Nef的不同进化枝的组分。 本发明的疫苗还可以包括V1，V2，V3或V4缺失或其组合。 在另一个实施方案中，本发明提供了多重HIV包膜免疫原。
-
7.发明申请OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND OTHER VIRUSES 审中-公开优化疫苗提供针对EBOLA和其他病毒的保护公开(公告)号：US20120156239A1
公开(公告)日：2012-06-21
申请号：US13349917
申请日：2012-01-13
申请人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
发明人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5156 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/17022 , C12N2760/14022 , C12N2760/14134 , C12N2840/44
摘要： The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
摘要翻译： 本发明涉及包含编码经修饰的病毒糖蛋白（GP）的多核苷酸的核酸分子，其具有位于所述GP的相对保守区域中的至少一个氨基酸改变，其降低体外细胞毒性并且与体外细胞毒性相比保留免疫原性 野生型病毒GP和相关修饰的病毒GP，质粒DNA，重组病毒，腺病毒，药物组合物，疫苗组合物，与修饰的病毒GP特异性反应的抗体的免疫原性及其制备和使用的相关方法。
-
8.发明授权Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector 有权包含人密码子优化的马尔堡病毒（MARV）安哥拉糖蛋白基因插入片段的重组表达载体和使用所述载体的免疫方法公开(公告)号：US08101739B2
公开(公告)日：2012-01-24
申请号：US11662869
申请日：2005-09-27
申请人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
发明人： Nancy Sullivan , Bimal Chakrabarti , Zhi-Yong Yang , Maria Grazia Pau , Jaap Goudsmit , Gary Nabel
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5156 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/17022 , C12N2760/14022 , C12N2760/14134 , C12N2840/44
摘要： The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
摘要翻译： 本发明涉及包含编码经修饰的病毒糖蛋白（GP）的多核苷酸的核酸分子，其具有位于所述GP的相对保守区域中的至少一个氨基酸改变，其降低体外细胞毒性并且与体外细胞毒性相比保留免疫原性 野生型病毒GP和相关修饰的病毒GP，质粒DNA，重组病毒，腺病毒，药物组合物，疫苗组合物，与修饰的病毒GP特异性反应的抗体的免疫原性及其制备和使用的相关方法。
-
9.发明申请公开(公告)号：US20060148087A1
公开(公告)日：2006-07-06
申请号：US10997120
申请日：2004-11-24
申请人： Gary Nabel , Zhi-yong Yang
发明人： Gary Nabel , Zhi-yong Yang
IPC分类号： C12N15/86
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , A61K2039/70 , C12N2710/10343 , C12N2760/14122 , C12N2760/14134 , C12N2760/14222
摘要： The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
摘要翻译： 本发明一般涉及病毒疫苗，更具体地涉及针对由病毒感染引起的病毒或疾病引起免疫应答的病毒疫苗和方法。
-
公开(公告)号：US20130251726A1
公开(公告)日：2013-09-26
申请号：US13792098
申请日：2013-03-10
申请人： John Mascola , Dennis R. Burton , Wayne Koff , Peter Kwong , Gary Nabel , Sanjay K. Phogat , Pascal Raymond Georges Poignard , Melissa Danielle De Jean St. Marcel Simek-Lemos , Xueling Wu , Tongqing Zhou , Zhi-Yong Yang
发明人： John Mascola , Dennis R. Burton , Wayne Koff , Peter Kwong , Gary Nabel , Sanjay K. Phogat , Pascal Raymond Georges Poignard , Melissa Danielle De Jean St. Marcel Simek-Lemos , Xueling Wu , Tongqing Zhou , Zhi-Yong Yang
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/56988
摘要： The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
摘要翻译： 本申请涉及新型HIV-1广泛中和抗体。 本发明的抗体的特征还在于它们能够结合来自Env蛋白的表位。 本发明还提供轻链和重链可变区序列。 提供了预防，诊断和治疗艾滋病毒感染的组合。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.024 秒)
